Details of the Active Pharmaceutical Ingredient (API)
General Information of API (ID: D00040) | |||||
---|---|---|---|---|---|
Name |
Apixaban
|
||||
Synonyms |
Click to Show/Hide the Synonyms of This API
Apixaban; 503612-47-3; Eliquis; BMS-562247-01; BMS 562247-01; BMS-562247; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; UNII-3Z9Y7UWC1J; 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; 3Z9Y7UWC1J; CHEMBL231779; CHEBI:72296; 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide; BMS562247-01; 1-(4-Methoxy-phenyl)-7-oxo-6-[4-(2-oxo-piperidin-1-yl)-phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxylic acid amide; 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5-dihydropyrazolo[5,4-c]pyridine-3-carboxamide; Eliquis (TN); Apixaban(BMS-562247-01); apixabanum; Apixaban (JAN/USAN/INN); Apixaban [USAN:INN:JAN]; Apixabin; HSDB 8223; Apixaban - Adooq Bioscience; 1H-Pyrazolo[3,4-c]pyridine-3-carboxamide, 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-; cc-395; MLS006010026; SCHEMBL118023; GTPL6390; PYR431; Apixaban BMS-562247-01; Apixaban,BMS-562247-01; BDBM19023; DTXSID80436500; EX-A048; BCPP000396; HMS3655O07; AOB87769; BCP02451; Apixaban (BMS 562247-01); Apixaban/BMS562247-01/Apixaban; ABP000333; CA0186; MFCD11977295; NSC784102; ZINC11677837; AKOS005146204; BCP9000310; CCG-229675; CS-0401; DB06605; ME-0152; NSC-784102; PB10976; QC-8191; NCGC00346555-01; NCGC00346555-02; NCGC00346555-05; NCGC00346555-08; AC-26301; AK161862; HY-50667; SMR004676529; AB0007933; FT-0686944; SW220177-1; D03213; Q-4456; AB01565766_02; 612A473; AR-270/43507990; Q414462; J-200194; 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo(3,4c)pyridine-3-carboxamide; 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo piperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxo-1-piperidinyl)phenyl]-4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c]pyridine-3-carboxamide; 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-1H,4H,5H,6H,7H-pyrazolo[3,4-c]pyridine-3-carboxamide; 1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide?BMS-562247; BMS-562247-01; 1H-Pyrazolo(3,4-c)pyridine-3-carboxamide,4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxo-1-piperidinyl)phenyl)-
|
||||
Clinical Status |
Approved
|
||||
Disease Indication | Deep vein thrombosis | ICD-11: BD71 | [1] | ||
PubChem CID | |||||
Formula |
C25H25N5O4
|
||||
Canonical SMILES |
COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N
|
||||
InChI |
1S/C25H25N5O4/c1-34-19-11-9-18(10-12-19)30-23-20(22(27-30)24(26)32)13-15-29(25(23)33)17-7-5-16(6-8-17)28-14-3-2-4-21(28)31/h5-12H,2-4,13-15H2,1H3,(H2,26,32)
|
||||
InChIKey |
QNZCBYKSOIHPEH-UHFFFAOYSA-N
|
||||
Click to Show/Hide the Molecular Data (Structure/Property) of This API | |||||
Structure |
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=10182969"></iframe>
|
||||
3D MOL | 2D MOL | ||||
Physicochemical Properties | Molecular Weight | 459.5 | Topological Polar Surface Area | 111 | |
XlogP | 2.2 | Complexity | 777 | ||
Heavy Atom Count | 34 | Rotatable Bond Count | 5 | ||
Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 5 | ||
Full List of Drug Formulations (DFMs) Containing This API | ||||||
---|---|---|---|---|---|---|
Apixaban 2.5 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Ferric oxide yellow; Titanium dioxide; Triacetin; Croscarmellose sodium; Hypromellose, unspecified; Microcrystalline cellulose
|
|||||
Dosage Form | Oral Tablet | |||||
Company | A-S Medication Solutions; Cardinal Health; E.R. Squibb & Sons | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [3] | |||
Apixaban 5 mg tablet | Click to Show/Hide the Full List of Formulation(s): 1 Formulation(s) | |||||
Drug Formulation 1 | DFM Info click to show the detail info of this DFM | |||||
All DIGs | Click to Show/Hide the Full List of DIGs in This DFM
Anhydrous lactose; Lactose monohydrate; Sodium lauryl sulfate; Magnesium stearate; Ferric oxide red; Titanium dioxide; Triacetin; Croscarmellose sodium; Hypromellose, unspecified; Microcrystalline cellulose
|
|||||
Dosage Form | Oral Tablet | |||||
Company | A-S Medication Solutions; Cardinal Health; E.R. Squibb & Sons | |||||
DIG(s) with Biological Activity | ||||||
DIG Name | DIG Info | Representative Biological Activity of This DIG | REF | |||
Sodium lauryl sulfate | DIG Info | Solute carrier SLCO2B1 (Ki = 1.98 uM) | [2] | |||
Magnesium stearate | DIG Info | Albendazole monooxygenase (Protein expression downregulation) | [3] | |||
Carmellose sodium | DIG Info | Albendazole monooxygenase (Protein expression upregulation) | [3] | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.